Authors
Latest:
Advice and Future Directions for the Treatment of GISTEdwin Choy, MD, provides key recommendations for community oncologists treating patients with gastrointestinal stromal tumor.
Latest:
Bridging Science and Compassion in Cancer CareIn the second episode of Emerging Experts, Hemali Batra-Sharma, MD, discusses her passion for oncology and some of the experiences that have helped to shape her career.
Latest:
Early Detection & the Right Treatment Critical for Prostate CancerJohn E. Sylvester, MD, a radiation oncologist with GenesisCare, reviews the importance of treating prostate cancer at the earliest stage possible.
Latest:
Radiation Safety Measures and Precautions for Prostate CancerScott T. Tagawa, MD, MS, FACP, FASCO, highlights a key difference between oral androgen receptor inhibitor drugs and therapeutic radionuclides for the treatment of prostate cancer.
Latest:
Addressing Dosing Methods With Teclistamab in Multiple MyelomaEmma Searle, PhD, discusses the dosing approach of the MajestTEC-2 trial (NCT04722146) and sequencing teclistamab (Tecvayli) in patients with multiple myeloma.
Latest:
Durvalumab After Chemotherapy Helps Manage Toxicities in NSCLC TreatmentChemotherapy for the treatment of non-small cell lung cancer can be quite toxic, however, durvalumab after chemotherapy can help manage toxicities while improving overall survival, according to the PACFIC trial.
Latest:
Importance of Patient-Reported Outcomes in the GRIFFIN StudyRebecca Silbermann, MD, MMS, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study and the importance of individualizing treatment for patients with multiple myeloma.
Latest:
Analyzing the ESPAC-5F Trial in Borderline Resectable Pancreatic CancerShubham Pant, MD, discusses the ESPAC-5F trial methods and efficacy in patients with pancreatic cancer.
Latest:
How Do These Data Apply to Community Oncologists?Explanation of how these data apply to community oncologists.
Latest:
Sequencing Therapies in the First and Second Line for Patients With HCCLipika Goyal, MD, discusses first-line options for patients with patients with hepatocellular carcinoma.
Latest:
Advances in CAR T-Cell Therapy in Hematologic MalignanciesKruti Patel, DO, reviews the advancements, landmark trials, and challenges with CAR T-cell therapy for Cancer Immunotherapy Month.
Latest:
Key Clinical Insights for the Management of Newly Diagnosed Multiple MyelomaPractical insights for the management of patients with NDMM.
Latest:
Loncastuximab Shows Favorable Tolerability in Relapsed/Refractory DLBCLMatthew S. McKinney, MD, discusses the tolerability observed in the LOTIS-2 trial of loncastuximab tesirine of patients with relapsed/refractory diffuse large B-cell lymphoma.
Latest:
Zolbetuximab Plus mFOLFOX for CLDN18.2+/HER2- Advanced Gastric/GEJ CancersSamuel Klempner, MD, explains the rationale for the phase 3 SPOTLIGHT study.
Latest:
Recommendations for Diagnosing and Treating Rare Histiocytic NeoplasmsRonald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.
Latest:
Olszewski Recaps Results of Mosunetuzumab in Elderly/Unfit DLBCLAdam J. Olszewski, MD, discusses the promising results of a phase 1b/2 study of mosunetuzumab for elderly/unfit patients with previously untreated diffuse large B-cell lymphoma.
Latest:
Emerging Therapies Are Explored in Low- and High-Risk MDSFor patients who are ineligible for erythropoiesis-stimulating agents, luspatercept-aamt offers a new approach.
Latest:
Thomas Discusses Non-Melanoma Skin CancersValencia D. Thomas, MD, MHCM, discusses the current landscape for patients with non-melanoma skin cancers.
Latest:
Desai on Embracing Curiosity and Change in the Oncology FieldIn the first episode of Emerging Experts, Aakash Desai, MD, MPH, discusses his journey through the oncology field by reminiscing on the encouraging guidance of his mentors, personal research goals, and his experiences thus far as an oncologist.
Latest:
Bispecific T-Cell Engagers Improve Immune Response in Multiple MyelomaThomas G. Martin, MD, discusses the mechanism of action of bispecific T-cell engagers including teclistamab-cqyv in patients with relapsed/refractory multiple myeloma.
Latest:
Bahary on the Response to Chemotherapy Drug Shortages at AHNNathan Bahary, MD, PhD, discusses how Allegheny Health Network has been able to combat the recent chemotherapy drug shortages seen nationwide.
Latest:
Molecular Subtyping Leads to New Targeted Trials in Endometrial CancerRuchi Garg, MD, discusses the impact of targeted therapies studies in patients with early and recurrent endometrial cancer.
Latest:
Lu 177 Vipivotide Tetraxetan Approved for PSMA-Positive mCRPCRichard L. Wahl, MD, discusses the approval of lutetium Lu 177 vipivotide tetraxetan for patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
Latest:
Palliative Care Plays Important Role in Advanced CancersKavitha Ramchandran, MD, discusses the role of palliative care for patients with cancer, particularly those with advanced stage disease.
Latest:
Ongoing Trials Investigate Amivantamab Combinations for EGFR+ NSCLCMelina E. Marmarelis, MD, reports the study design of the Chrysalis-2 trial and ongoing trials researching the combination of amivantamab and lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer.
Latest:
The Future of Breast Cancer Care: Blackwood on Personalized ApproachesIn this episode of Targeted Talks, M. Michele Blackwood, MD, FACS, discusses the current landscape of breast cancer treatment and how personalized medicine with genomic testing is changing the field.
Latest:
Bemcentinib/Pembrolizumab Shows Clinical Activity, Tolerability in Advanced NSCLCPatients with checkpoint inhibitor-naïve and refractory composite AXL-positive non—small cell lung cancer, responded to treatmen with the first-in-class oral kinase inhibitor bemcentinib in combination with pembrolizumab, and the compound was well-tolerated, according to updated results from the phase 2 BGBC008 clinical trial.
Latest:
Evaluating the Feasibility of Liso-cel Administration in the Outpatient SettingCarlos R. Bachier, MD, discusses how an analysis of 3 clinical trials evaluating the efficacy of lisocabtagene maraleucel demonstrated the feasibility of outpatient administration of chimeric antigen receptor T-cell therapy.
